In recent years, advances in melanoma treatment have renewed patient hope. This
comprehensive review emphasizes the evolving treatment landscape, particularly …

Historically, stage III–IV melanoma patients have had few options to achieve long-term
survival. For patients with stage III disease, surgery alone may be curative for approximately …

Metastatic melanoma therapies have proliferated over the last ten years. Prior to this,
decades passed with only very few drugs available to offer our patients, and even then …

The prognosis for patients with stage IV melanoma has historically been extremely poor and
there have until recently been no effective treatment options. The last 3 years have seen a …

Before 2011, patients with advanced or metastatic melanoma had a particularly poor long-
term prognosis. Since traditional treatments failed to confer a survival benefit, patients were …

Background Although a myriad of novel treatments entered the treatment paradigm for
advanced melanoma, there is lack of head-to-head evidence. We conducted a network meta …

Background Treatment options for advanced melanoma have increased with the US Food
and Drug Administration approval of the anti-LAG3 plus anti-PD-1 relatlimab/nivolumab …

The melanoma field has seen an unprecedented set of clinical advances over the past
decade. Therapeutic efficacy for advanced or metastatic melanoma went from being one of …

7511 Background: Despite tremendous effort towards the development of novel treatments
for advanced melanoma, a significant survival benefit has not been clearly documented. The …

Despite advances in early detection as described in part 1 of this continuing medical
education series, melanoma continues to be a large contributor to cutaneous cancer-related …